Latest news with #DiabetesMedicalTechnology
Business Insider
6 days ago
- Business
- Business Insider
Insulet initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Insulet (PODD) with a Buy rating and $380 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and Insulet stands to benefit from accelerating adoption of patch pump technology with the company being the only participant in the category today, the analyst tells investors in a research note. The company's pipeline also offers the potential to further strengthen its relative position, while its sustained top-line growth should support outsized adjusted EBITDA results, Goldman Sachs added. Confident Investing Starts Here:
Business Insider
6 days ago
- Business
- Business Insider
DexCom initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of DexCom (DXCM) with a Buy rating and $104 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and DexCom offers potential upside from consumer-related adoption and strong profitability leverage that should evidence through the balance of 2025, the analyst tells investors in a research note. The market also underappreciates the degree of P&L upside in DexCom model as gross margins scale, Goldman Sachs added. Confident Investing Starts Here:
Business Insider
6 days ago
- Business
- Business Insider
Beta Bionics initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst David Roman initiated coverage of Beta Bionics (BBNX) with a Neutral rating and $16 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and Beta Bionics technology is well suited for a targeted segment of the Type 1 market, the analyst tells investors in a research note. Goldman Sachs added however that while the company's near-term growth should outpace Diabetes peers and SMID cap MedTech, consensus estimates seem to largely capture the opportunity over the next several years, with valuation reflecting both that level of growth and the need to raise capital down the road to achieve cash flow breakeven. Confident Investing Starts Here:
